Where MACI sits in the cartilage repair pathway

The right repair for a damaged knee depends heavily on what has actually been damaged — and how much of it. For most patients researching MACI, the most useful starting point is understanding where it sits in the treatment hierarchy: beyond injection or biologic support, but well short of joint replacement. It belongs firmly in the restoration tier, where the aim is to rebuild structurally sound cartilage in a discrete, contained area of damage.

MACi targets full-thickness cartilage defects — lesions in which cartilage has worn entirely through to the underlying bone, rather than simply thinned at the surface. These are classified as ICRS Grade 3 or 4, and they typically occur on the femoral condyle or the patellofemoral surface. The focal nature of the defect matters: patients with damage confined to one or two discrete areas are the appropriate candidates. Where cartilage loss is diffuse — affecting multiple compartments or the whole knee — focal repair of any kind becomes impractical, and a different pathway is needed.

Defect size guides technique selection within the restoration tier. For lesions smaller than approximately 2 cm², marrow-stimulation procedures or osteochondral autograft remain reasonable options. The SUMMIT Phase 3 RCT demonstrated that MACI's advantage over microfracture becomes clearest for defects of 3 cm² or greater, where it produced superior KOOS pain and function scores at both two and five years. MACI also improves on first-generation ACI by seeding chondrocytes directly onto a Type I/III collagen scaffold rather than relying on a periosteal patch, reducing the technical variability associated with earlier techniques.

The two-stage process: what happens between the first and second operation

Standard MACI unfolds across two separate operations, with a laboratory interval in between — and understanding that sequence helps set realistic expectations from the outset.

First operation. Under general or regional anaesthesia, a surgeon arthroscopically harvests a small sample of cartilage from a non-weight-bearing area of the knee. The procedure is relatively brief, and most patients recover from it within a few days.

Laboratory phase. The harvested tissue is sent to a Good Manufacturing Practice (GMP) facility, where laboratory scientists isolate the chondrocytes and culture them over approximately three to four weeks. Once a sufficient cell population has been established, those cells are seeded directly onto the porcine Type I/III collagen scaffold that will eventually be implanted. This expansion step is what defines the two-stage approach: it produces a higher, standardised chondrocyte dose than freshly harvested tissue alone could provide. That biological rationale is the core reason for the intervening wait.

Second operation. At the second sitting — again under anaesthesia — the surgeon opens the joint, prepares the defect bed to create a stable shoulder, cuts the cell-seeded scaffold to fit, and secures it in place, typically with fibrin glue. Long-term follow-up data, including Minas et al.'s minimum ten-year ACI series and Ebert et al.'s five-year MACI dataset, suggest the resulting repair tissue can remain durable well beyond the immediate post-operative period.

Two anaesthetics, two recovery periods, and a logistical gap of roughly a month are inherent features of this pathway — practical considerations that the single-stage alternative described in the next section is designed to address.

Single-stage MACI (STACi): collapsing two operations into one

Collapsing those two operations into one is the central innovation of STACi (Single Treatment Autologous Chondrocyte Implantation). Rather than dispatching harvested cartilage to a GMP facility, the surgical team brings the processing capability into the operating theatre itself, allowing chondrocyte isolation and scaffold assembly to occur while the patient is still on the table.

The intraoperative preparation follows four defined steps. Cartilage fragments are harvested from a non-weight-bearing zone and enzymatically digested to free the chondrocytes — without any cell expansion. Simultaneously, bone marrow is aspirated and mesenchymal stem cells (MSCs) are concentrated, washed, and counted. The fresh chondrocytes and the MSC concentrate are then combined on a collagen and hyaluronan scaffold, with platelet-rich plasma (PRP) or hyaluronan added as a biological adjuvant, and the construct is implanted before the patient leaves theatre.

The biological strategy differs from standard MACI in a meaningful way. Where the two-stage approach delivers a large, laboratory-expanded chondrocyte dose, STACi relies on a smaller but entirely fresh cell population supported by MSC co-delivery. Those MSCs are understood to act as paracrine directors — releasing growth factors that guide and stimulate chondrocyte activity at the repair site. Taylor and Lee set out this reasoning in detail in their 2019 account of the technique.

One practical advantage of the single-session format is the ability to treat more than one defect area at the same time. Medial femoral condyle damage and patellofemoral cartilage loss, for example, can both be addressed in the same sitting — an arrangement that is difficult to plan reliably across two separate staged procedures.

Clinical experience from the London Cartilage Clinic's STACi pathway, developed by Professor Paul Lee, has been positive in early application. No powered randomised controlled trial comparing STACi directly with two-stage MACI has yet been published — a factual gap addressed in the evidence section below.

Who is the right candidate — and who is not

Not every patient with knee pain and a cartilage lesion is a suitable candidate — and a clear understanding of the selection criteria shapes what happens at a first consultation.

The shared starting point for both two-stage MACI and STACi is a symptomatic, focal, full-thickness lesion (ICRS Grade 3 or 4) — most commonly on the femoral condyle or the patellofemoral surface — in a knee that retains adequate bone stock and is otherwise mechanically stable. Both techniques are intended for adults, and both lose their rationale where cartilage loss is diffuse rather than focal: widespread arthritis throughout the joint cannot realistically be reversed with a scaffold-based repair.

Where the two approaches part company is on age. STACi is the technique most commonly offered to patients under 40, with appropriately selected patients up to around 45 considered depending on biological rather than strictly chronological age — joint health, activity level, and tissue quality matter more than the year of birth. Two-stage MACI carries no fixed upper age ceiling in its regulatory label, but the same principle applies in practice: advancing diffuse joint change shifts the conversation toward preservation or replacement rather than restoration.

Shared contraindications

• Widespread or whole-knee osteoarthritis
• Active inflammatory arthritis (e.g., rheumatoid)
• Significant ligamentous instability — unless corrected concurrently
• Inadequate subchondral bone stock

Mechanical alignment must also be assessed before committing to either procedure. A knee that loads unevenly will subject a repaired graft to forces it cannot sustain; where significant varus or valgus malalignment is present, a corrective osteotomy (HTO or DFO) is considered alongside — not instead of — the cartilage procedure.

Prior marrow-stimulation surgery (microfracture) is a relevant factor too. Changes to the subchondral bone plate that sometimes follow microfracture may complicate the repair environment and influence which technique is most appropriate — something assessed in detail at consultation.

What the clinical evidence shows

The SUMMIT Phase 3 RCT remains the strongest controlled comparison in this field — its finding that MACI produced significantly superior KOOS pain and function scores against microfracture at both two and five years, for defects of 3 cm² or larger, was set out in the opening section. Two further datasets extend the picture beyond the mid-term. Minas and colleagues, in a minimum ten-year ACI follow-up that earned the John Insall Award and was published in Clinical Orthopaedics and Related Research in 2014, demonstrated that the clinical gains of cell-based repair hold well beyond the five-year horizon where most cartilage trials end. Ebert et al. add complementary MRI evidence: their five-year MACI dataset shows scaffold integration alongside sustained functional improvement, a useful signal that imaging findings and patient-reported outcomes are moving in the same direction.

Single-stage scaffold approaches — AMIC in particular — provide adjacent data, but the mechanism is materially different: AMIC augments marrow stimulation with a collagen membrane but contains no harvested cell component. It is not a proxy for STACi outcomes.

For STACi, no powered randomised controlled trial against standard two-stage MACI has been published. The current evidence rests on biological rationale, the intraoperative logic of MSC paracrine support, and early clinical experience at specialist centres. That is a genuine limitation worth naming: the technique is biologically coherent and early application has been encouraging, but it awaits the kind of independent prospective data that now gives standard MACI its clinical footing.

Recovery expectations and getting assessed

Recovery after either procedure is measured in months, not weeks — and that commitment deserves honest framing before a patient decides to proceed.

The early phase focuses on protecting the implanted construct while it begins to integrate with the surrounding tissue. Weight-bearing is restricted and range-of-motion introduced gradually; premature loading in this window risks scaffold disruption before the repair has matured sufficiently to tolerate stress. From there, the pathway moves through metabolic conditioning, progressive strengthening, and neuromuscular training — each phase gated by clinical and functional markers rather than a fixed date.

For most patients, meaningful functional recovery takes nine to twelve months. Those returning to competitive sport should allow twelve months or beyond, with return determined by objective milestones — strength symmetry, hop-test performance, and readiness under load — rather than a calendar. This is one of the sharper practical contrasts with microfracture, which carries a shorter nominal recovery timeline but a different biological trade-off at two to three years.

Establishing which procedure fits a given patient requires a structured clinical assessment: MRI review to characterise defect size and subchondral bone involvement, evaluation of mechanical alignment, and a detailed discussion of activity demands and prior surgical history — the factors that together determine whether standard two-stage MACI, STACi, or another approach is most appropriate. Patients in London can arrange that conversation via londoncartilage.com.